Net sales rose to SEK 22.0 million for H1 2024, driven by milestone payments, but EBITDA and net income declined year-over-year. Strategic investments in inventory and product development continue as Ortoma advances commercialization and regulatory approvals.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.